A new daily eye drop costing just $3 could help millions of middle-aged adults see clearly without needing reading glasses.
The treatment, called VIZZ, has just been approved in the US and is the first designed specifically to treat presbyopia – the natural age-related decline in near vision that affects almost everyone over 45.
Instead of altering the shape of the eye’s lens, the drops work in a different way.
They gently shrink the pupil to create what doctors call a ‘pinhole effect’ – similar to the way squinting can bring blurred text into focus.
By reducing the amount of stray light entering the eye, the drops allow only the most focused light rays to reach the retina.
This increases depth of focus, making close-up objects like phone screens, menus and books appear sharper again.
In clinical trials, the results were striking.
Around 71 per cent of users experienced a noticeable improvement in their near vision within just 30 minutes of using the drops.
More than 128 million American adults age 45 and older have presbyopia, struggling to read menus and smartphone text, and relying on reading glasses to get by
For many, the effects lasted up to 10 hours – covering most of the day.
That means a single daily dose could allow users to read, text and work without constantly reaching for glasses.
Presbyopia is caused by the gradual stiffening of the eye’s lens, which begins in a person’s 40s. Over time, the lens loses its flexibility and can no longer easily switch focus from distant objects to things up close.
For decades, the only real solutions have been reading glasses, bifocals or contact lenses – leaving many people juggling multiple pairs or repeatedly putting glasses on and taking them off throughout the day.
VIZZ offers a simpler alternative.
Its active ingredient, aceclidine, has been used in ophthalmology for years but has now been refined into a form that specifically targets the iris – the coloured part of the eye – rather than the lens itself.
Crucially, this means the drops improve near vision without compromising distance sight – a common drawback with some other treatments.
In clinical trials, VIZZ improved near vision within 30 minutes for 71 percent of users, with 40 percent still experiencing that same level of improvement 10 hours later
The approval is based on data from multiple late-stage trials involving hundreds of participants. In one set of studies, 466 people used the drops daily over six weeks, with further research assessing longer-term safety.
No serious side effects were reported.
The most common reactions included mild eye irritation, temporary redness and slightly dimmed vision shortly after application. These effects were typically short-lived and resolved on their own.
Some users have already reported dramatic improvements.
One said they were able to read their phone without glasses for the first time in five years within 20 minutes of using the drops.
Doctors say the treatment could mark a significant shift in how presbyopia is managed.
‘This will be a welcome solution,’ one clinical investigator involved in the trials said, adding that it could quickly become a widely used option for both optometrists and ophthalmologists.
However, experts caution that the drops may not completely eliminate the need for reading glasses in every situation – particularly in low light or when reading very fine print.
Even so, with more than 100 million adults affected by presbyopia in the US alone, the potential impact is huge.
As populations continue to age, simple, non-invasive treatments like VIZZ are expected to become increasingly important.
For millions tired of hunting for their glasses, the idea of restoring clear near vision with a single drop a day could be a game-changer.
